` RVX (Resverlogix Corp) vs S&P TSX Composite Index (Canada) Comparison - Alpha Spread

RVX
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, RVX has significantly outperformed S&P TSX Composite Index (Canada), delivering a return of +170% compared to the S&P TSX Composite Index (Canada)'s +19% growth.

Stocks Performance
RVX vs S&P TSX Composite Index (Canada)

Loading
RVX
S&P TSX Composite Index (Canada)
Add Stock

Performance Gap
RVX vs S&P TSX Composite Index (Canada)

Loading
RVX
S&P TSX Composite Index (Canada)
Difference
www.alphaspread.com

Performance By Year
RVX vs S&P TSX Composite Index (Canada)

Loading
RVX
S&P TSX Composite Index (Canada)
Add Stock

Competitors Performance
Resverlogix Corp vs Peers

S&P TSX Composite Index (Canada)
RVX
ABBV
AMGN
GILD
VRTX
Add Stock

Resverlogix Corp
Glance View

Market Cap
38.3m CAD
Industry
Biotechnology

Resverlogix Corp. engages in the research and development of pharmaceutical products for cardiovascular diseases. The company is headquartered in Calgary, Alberta and currently employs 22 full-time employees. The company went IPO on 2001-10-12. The firm is developing apabetalone (RVX-208), a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that regulates disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. The selective inhibition of apabetalone on BD2 produces a specific set of biological effects for patients with chronic disease, including cardiovascular disease (CVD) and associated comorbidities, and COVID-19. The firm is in the development stage as it is focused on research and development. The firm has not earned any revenue.

RVX Intrinsic Value
Not Available
Back to Top